Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz I, Perelló A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Máhr K, Schenker M, Sohn J, Lee KS, Shepherd CJ, Oelmann E, Sarker SJ, Prendergast A, Marosics P, Moosa A, Lawrence C, Coetzee C, Mousa K, Cortés J.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2526. [Epub ahead of print]

PMID:
31465093
2.

Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma.

Oelmann E, Stein H, Berdel WE, Herbst H.

PLoS One. 2015 Sep 25;10(9):e0138747. doi: 10.1371/journal.pone.0138747. eCollection 2015.

3.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U.

Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422. Epub 2015 Mar 24.

4.

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.

Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U.

Br J Cancer. 2012 Sep 25;107(7):1093-9. doi: 10.1038/bjc.2012.368. Epub 2012 Aug 30.

5.

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.

Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, Müller-Tidow C, Kolkmeyer A, Büchner T, Serve H, Berdel WE.

Mol Cancer Ther. 2006 Dec;5(12):3105-12.

6.

Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.

Berdel WE, Kulimova E, Kolkmeyer A, Zühlsdorf M, Serve H, Büchner T, Oelmann E.

Ann Hematol. 2005 Nov;84(12):771-3. Epub 2005 Nov 12.

PMID:
16094532
7.

Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro.

Oelmann E, Haghgu S, Kulimova E, Mesters RM, Kienast J, Herbst H, Schmitmann C, Kolkmeyer A, Serve H, Berdel WE.

Int J Oncol. 2004 Oct;25(4):1001-12.

PMID:
15375550
8.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

PMID:
15090450
9.

Re: Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development.

Oelmann E, Haghgu S, Kulimova E, Serve H, Schmitmann C, Berdel WE.

J Natl Cancer Inst. 2003 Aug 6;95(15):1171-3; author reply 1173-4. No abstract available.

PMID:
12902450
10.

Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial.

Oelmann E, Thomas M, Serve H, Kienast J, Zühlsdorf M, Mohr M, Klinke F, Dölken G, Macha H, Schmidt EW, Berdel WE.

Oncology. 2002;63(3):248-53.

PMID:
12381904
11.

Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma.

Retzlaff S, Padró T, Koch P, Oelmann E, Lügering N, Mesters RM, Berdel WE.

Oncol Rep. 2002 May-Jun;9(3):525-7.

PMID:
11956621
12.

Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells.

Oelmann E, Herbst H, Zühlsdorf M, Albrecht O, Nolte A, Schmitmann C, Manzke O, Diehl V, Stein H, Berdel WE.

Blood. 2002 Jan 1;99(1):258-67.

PMID:
11756180
13.

Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma.

Mohr M, Dalmis F, Hilgenfeld E, Oelmann E, Zühlsdorf M, Kratz-Albers K, Nolte A, Schmitmann C, Onaldi-Mohr D, Cassens U, Serve H, Sibrowski W, Kienast J, Berdel WE.

Clin Cancer Res. 2001 Jan;7(1):51-7.

14.

Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells.

Fenski R, Flesch K, Serve S, Mizuki M, Oelmann E, Kratz-Albers K, Kienast J, Leo R, Schwartz S, Berdel WE, Serve H.

Br J Haematol. 2000 Feb;108(2):322-30.

PMID:
10691863
15.

Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1.

Oelmann E, Kraemer A, Serve H, Reufi B, Oberberg D, Patt S, Herbst H, Stein H, Thiel E, Berdel WE.

Int J Cancer. 1997 Jun 11;71(6):1066-76.

16.

Fresh peripheral blood mononuclear cell preparations are a better starting material than bone marrow after cryopreservation for immunomagnetic harvesting of CD34(+) hematopoietic cells.

Papadimitriou C, Roots A, Koenigsmann M, Oelmann E, Topp M, Oberberg D, Reufi B, Thiel E, Berdel W.

Int J Oncol. 1996 Dec;9(6):1107-12.

PMID:
21541618
17.

Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13.

Serve H, Oelmann E, Herweg A, Oberberg D, Serve S, Reufi B, Mücke C, Minty A, Thiel E, Berdel WE.

Cancer Res. 1996 Aug 1;56(15):3583-8.

18.

Immunomagnetic selection of CD34+ cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques.

Papadimitriou CA, Roots A, Koenigsmann M, Koenigsmann M, Mücke C, Oelmann E, Oberberg D, Reufi B, Thiel E, Berdel WE.

J Hematother. 1995 Dec;4(6):539-44.

PMID:
8846014
19.

Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines.

Papadimitriou CA, Topp MS, Serve H, Oelmann E, Koenigsmann M, Maurer J, Oberberg D, Reufi B, Thiel E, Berdel WE.

Eur J Cancer. 1995 Dec;31A(13-14):2371-8.

PMID:
8652271
20.

Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism.

Topp MS, Papadimitriou CA, Eitelbach F, Oelmann E, Koehler B, Oberberg D, Von Marschall Z, Reufi B, Stein H, Thiel E, et al.

Leuk Lymphoma. 1995 Oct;19(3-4):319-28.

PMID:
8535226
21.

Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies.

Topp MS, Papadimitriou CA, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, Oberberg D, Reufi B, Stein H, Thiel E, et al.

Cancer Res. 1995 May 15;55(10):2173-6.

22.

Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling.

Oelmann E, Sreter L, Schuller I, Serve H, Koenigsmann M, Wiedenmann B, Oberberg D, Reufi B, Thiel E, Berdel WE.

Cancer Res. 1995 May 15;55(10):2212-9.

23.

Interleukin-1 receptor antagonist inhibits growth modulation of human tumor-cell lines by interleukin-1 in-vitro.

Oelmann E, Topp M, Reufi B, Papadimitriou C, Koenigsmann M, Oberberg D, Thiel E, Berdel W.

Int J Oncol. 1994 Mar;4(3):555-8.

PMID:
21566958
24.

Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases.

Foss HD, Herbst H, Oelmann E, Samol J, Grebe M, Blankenstein T, Matthes J, Qin ZH, Falini B, Pileri S, et al.

Br J Haematol. 1993 Aug;84(4):627-35.

PMID:
8217820

Supplemental Content

Loading ...
Support Center